클래스 II AI 의료 영상 소프트웨어 시장 : 시장 예측(2026-2032년)

The Class II AI Medical Imaging Software Market is projected to grow by USD 1,438.30 million at a CAGR of 8.54% by 2032.

Class II AI Medical Imaging Software: Executive Overview

Class II AI medical imaging software supports the analysis, prioritization, visualization, and workflow management of diagnostic images while operating within regulated medical-device frameworks. Its value proposition centers on improving clinical consistency, reducing avoidable delays, and helping healthcare professionals manage growing imaging workloads. Adoption depends on demonstrated clinical utility, regulatory authorization, interoperability, cybersecurity, and integration into established radiology and hospital workflows.

Regulatory, Workflow, and Evidence Shifts Reshape Adoption

The landscape is shifting from experimental demonstrations toward clinically governed deployment. Buyers increasingly assess software through evidence quality, intended-use clarity, human oversight, post-market monitoring, data protection, and compatibility with existing imaging and health-information systems. Reimbursement uncertainty, procurement complexity, and variation in regulatory requirements remain material barriers, while standardized reporting, cloud-enabled collaboration, and demand for operational efficiency support implementation.

Artificial Intelligence Extends Capacity but Does Not Replace Clinical Governance

Artificial intelligence is increasing the ability to detect patterns, prioritize urgent studies, quantify disease characteristics, and automate repetitive image-processing tasks. Its cumulative impact depends on representative training data, robust validation across scanners and care settings, transparent performance measurement, and appropriate clinician review. Bias, dataset shift, false positives, false negatives, explainability limitations, and automation bias require continuous monitoring and clearly defined escalation pathways.

Regional Conditions Create Distinct Adoption Pathways

North America is characterized by advanced digital infrastructure, established imaging networks, and strong emphasis on regulatory and clinical evidence. Europe combines sophisticated healthcare systems with stringent privacy, medical-device, and AI-governance expectations. Asia-Pacific presents substantial variation, with technologically advanced systems alongside rapidly expanding digital-health capacity. The Middle East is investing in centralized, digitally enabled healthcare delivery, while Africa faces infrastructure and workforce constraints but may benefit from scalable decision-support tools. Latin America shows growing interest in imaging modernization, tempered by uneven connectivity, procurement resources, and regulatory maturity.

Economic and Security Alliances Influence Standards and Procurement

ASEAN markets differ widely in regulatory readiness, infrastructure, and specialist availability, creating opportunities for interoperable and adaptable solutions. BRICS members reflect varied public-health priorities, domestic technology capabilities, and data-governance models. European Union adoption is shaped by coordinated privacy, medical-device, and AI requirements. G7 systems generally place strong weight on clinical evidence, cybersecurity, and integration. GCC countries are emphasizing digitally enabled care and centralized investment, while NATO members increasingly consider resilience, secure infrastructure, and continuity of clinical operations alongside performance.

Country Context Determines Implementation Priorities

Australia and Canada emphasize geographically distributed care, interoperability, and equitable access. Brazil, Mexico, India, and South Africa must balance expanding demand with uneven infrastructure, workforce capacity, and procurement constraints. China, Japan, and South Korea combine substantial technical capabilities with distinctive regulatory, data, and healthcare-system requirements. France, Germany, Italy, Spain, and the United Kingdom place significant emphasis on evidence, privacy, workflow integration, and public-sector value. The United States has a mature imaging ecosystem with rigorous attention to authorization, clinical validation, cybersecurity, and operational accountability. Russia's deployment environment is shaped by domestic infrastructure, regulatory conditions, and access considerations.

Prioritize Governed Deployment, Interoperability, and Measurable Clinical Value

Industry leaders should define narrow, clinically meaningful intended uses before scaling deployment; validate performance across relevant populations, modalities, devices, and care environments; and establish monitoring for drift, bias, safety events, and workflow effects. Solutions should integrate with existing imaging and clinical systems, provide usable explanations and confidence cues, and preserve clinician control. Procurement strategies should include cybersecurity, data residency, lifecycle support, training, change management, and transparent outcome metrics rather than relying on technical performance alone.

Methodology: Evidence-Based Synthesis of Regulatory and Clinical Drivers

This executive summary synthesizes the supplied market scope with established, publicly documented considerations relevant to Class II AI medical imaging software, including medical-device oversight, clinical validation, health-data governance, interoperability, cybersecurity, and healthcare delivery conditions across the specified geographies and country groupings. The analysis is qualitative and comparative. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific assessments.

Sustainable Adoption Depends on Trustworthy Integration

Class II AI medical imaging software can strengthen diagnostic workflows when it is implemented as a governed clinical support capability rather than an isolated algorithm. Durable adoption will depend on credible evidence, regulatory alignment, representative data, secure interoperability, clinician engagement, and continuous post-deployment oversight. Organizations that connect AI performance to measurable patient and operational outcomes will be better positioned to realize value while protecting safety, equity, and professional accountability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Class II AI Medical Imaging Software Market, by Modality

• 7.1. Introduction
• 7.2. Computed Tomography
• 7.3. Magnetic Resonance Imaging
• 7.4. Positron Emission Tomography
• 7.5. Ultrasound
• 7.6. X Ray

8. Class II AI Medical Imaging Software Market, by Software Type

• 8.1. Introduction
• 8.2. Integrated Software
• 8.3. Standalone Software

9. Class II AI Medical Imaging Software Market, by Algorithm Type

• 9.1. Introduction
• 9.2. Deep Learning
  • 9.2.1. Convolutional Neural Networks
  • 9.2.2. Generative Adversarial Networks
  • 9.2.3. Recurrent Neural Networks
• 9.3. Machine Learning
  • 9.3.1. Random Forest
  • 9.3.2. Support Vector Machines

10. Class II AI Medical Imaging Software Market, by Application

• 10.1. Introduction
• 10.2. Cardiology
  • 10.2.1. Arrhythmia Detection
  • 10.2.2. Coronary Artery Disease
  • 10.2.3. Heart Failure
• 10.3. Neurology
  • 10.3.1. Alzheimer's Detection
  • 10.3.2. Multiple Sclerosis
  • 10.3.3. Stroke Detection
• 10.4. Oncology
  • 10.4.1. Breast Cancer Detection
  • 10.4.2. Colon Cancer Detection
  • 10.4.3. Lung Cancer Detection
  • 10.4.4. Prostate Cancer Detection
• 10.5. Ophthalmology
  • 10.5.1. Diabetic Retinopathy
  • 10.5.2. Glaucoma Detection
  • 10.5.3. Macular Degeneration
• 10.6. Orthopedics
  • 10.6.1. Bone Density Analysis
  • 10.6.2. Fracture Detection
  • 10.6.3. Joint Analysis

11. Class II AI Medical Imaging Software Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Clinics
• 11.4. Diagnostic Centers
• 11.5. Hospitals

12. Class II AI Medical Imaging Software Market, by Deployment Mode

• 12.1. Introduction
• 12.2. Cloud
• 12.3. On Premise

13. Class II AI Medical Imaging Software Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Class II AI Medical Imaging Software Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Class II AI Medical Imaging Software Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agfa-Gevaert N.V.
• 17.2. Arterys Inc.
• 17.3. Canon Medical Systems Corporation
• 17.4. Caption Health, Inc.
• 17.5. Cleerly, Inc.
• 17.6. FUJIFILM Holdings Corporation
• 17.7. GE HealthCare Technologies Inc.
• 17.8. Hitachi, Ltd.
• 17.9. Hologic, Inc.
• 17.10. Koninklijke Philips N.V.
• 17.11. Samsung Medison Co., Ltd.
• 17.12. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 17.13. Siemens Healthineers AG
• 17.14. Subtle Medical, Inc.

18. Key Experts